Clinical Trials Logo

Plaque, Atherosclerotic clinical trials

View clinical trials related to Plaque, Atherosclerotic.

Filter by:

NCT ID: NCT02305862 Recruiting - Diabetes Mellitus Clinical Trials

A High-Resolution Magnetic Resonance Imaging Study to Evaluate the Effect of Rosuvastatin on Carotid Atherosclerotic Plaques

Start date: January 2013
Phase: N/A
Study type: Interventional

The aim of this study is to assess whether high intensive statin therapy could regress carotid atherosclerotic plaques as determined by High-Resolution Contrast Enhanced Magnetic Resonance imaging (CE-MRI). Enrolled patients have a baseline CE-MRI examination for screening carotid atherosclerotic plaques and are randomized to either low dose of Rosuvastatin (5mg) group or high dose of Rosuvastatin (20mg) group. After 26 weeks, all patients received CE-MRI examination again and each pair of baseline and follow-up CE-MRI assessments was analyzed in a blinded fashion. Moreover, lipid level and major adverse cardiovascular events are also evaluated during follow-up.

NCT ID: NCT02232360 Recruiting - Clinical trials for Coronary Artery Disease

Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone

Start date: January 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine effects of combination therapy with rosuvastatin and fenofibrate on atheromatous plaques and its tissue characteristics of de novo coronary lesions with intermediate stenosis in patient with coronary artery disease, compared with rosuvastatin alone therapy.

NCT ID: NCT01857687 Recruiting - Clinical trials for To Assess the Feasibility of CT-derived FFR, WSS and TPF on Coronary Atherosclerotic Plaque

Evaluation of FFR, WSS, and TPF Using CCTA

Start date: May 2013
Phase: N/A
Study type: Observational

To assess the feasibility of CT-derived computed fractional flow reserve (FFRCT), wall shear stress and total plaque force on coronary atherosclerotic plaque and to collect the preliminary data to apply those parameters for the prediction of clinical outcomes in patients with coronary artery stenosis.

NCT ID: NCT01608516 Recruiting - Inflammation Clinical Trials

Multimodal Imaging Assessment of the Inflammatory Atheromatous Plaque

Start date: April 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The present study aims at assessing the ability of 68Ga-NODAGA-RGD PET/CT for the detection of inflammatory atheromatous plaques in the carotid arteries, compared to 18F-FDG PET/CT, MRI and US and to determine the contribution of each imaging technique. Current gold standard for inflammation is histopathology. Hypothesis : 68Ga-NODAGA-RGD might give a better initial evaluation of patients with atheromatous plaques in the carotid artery eligible for endarterectomy.

NCT ID: NCT01238588 Recruiting - Inflammation Clinical Trials

The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan

Start date: November 2010
Phase: N/A
Study type: Interventional

The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will be associated with less inflammation including less atherosclerotic plaque inflammation (inflammation of the vessel walls).

NCT ID: NCT00920101 Recruiting - Inflammation Clinical Trials

Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging

Start date: June 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether HMG-CoA reductase inhibitor, atorvastatin attenuates inflammation in atherosclerotic plaques detected by 18F-fluorodeoxyglucose(FDG) PET.

NCT ID: NCT00760786 Recruiting - Clinical trials for Acute Coronary Syndrome

Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque

Start date: July 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether intensive lipid lowering and Omega-3 fatty acid are effective in the treatment of coronary atherosclerotic plaque.